« More Reaction Discovery (Now With Antibody Detection) |
| GSK Goes Hostile »
May 9, 2012
One More on That Buckyball Longevity Paper
I've received another e-mail from Prof. Fathi Moussa, lead author of the C60 longevity paper that's been discussed around here. I'd sent a list of the critiques that had shown up in the comments sections, and here's the reply:
An erratum with the right figures 3 and 4 will be published soon in Biomaterials. The right lifespan values after the beginning of the treatment are given in the original text without any change. To sum it up, the extensions of lifespans are twenty months and sixteen months with respect to water-treated controls and olive-oil-treated controls, respectively.
Our original objective was not to study lifespan extension but the toxic effects of C60 at reiterated doses. Lifespan extension by C60 is not really surprising, all the more so as it had already been shown by others that some C60-derivatives can prolong lifespans in several experimental models, albeit moderately.
What is really surprising in our results is that C60 acts at very low doses, which means that the effect is very strong, and that this effect lasts for a long time after the end of the administration. A possible explanation is that some C60 precipitated inside the reticulo-endothelial system and then slowly dissolves and diffuses.
Of course we understand that non C60 specialist readers are incredulous about these results, as it could be expected.
We hope now that others will try and confirm our results. If our results are confirmed by others, which we firmly believe, it will be then necessary to try to reproduce these experiments on bigger samples including other species and of course to optimize the dose and the duration of the treatment.
I share that hope that others will try to confirm the results. It'll be a while, most likely, before we hear about anything in this area, but when something comes up, I'll blog about it.
+ TrackBacks (0) | Category: Aging and Lifespan
POST A COMMENT
- RELATED ENTRIES
- Recent Clinical Trials
- Aileron and p53
- Asking the Employees
- A Vaccination Salute
- Some Sales Force
- More on TC-2153
- Giving Ambulance Chasing a Bad Name
- Antibiotic Resistance: A Question or Two